About Brainsway
Brainsway is a publicly listed company based in Jerusalem (Israel) founded in 2003. The company has 120 employees. Its website brainsway.com draws about 93 thousand monthly visits. Brainsway offers products and services including Deep TMS Device, Deep TMS for MDD, and Deep TMS for OCD. Its focus areas include Life Sciences, Neurology, Medical Devices and Therapeutic Devices. Its legal entity is BrainsWay Ltd. Its competitors include Magnus Medical and SYNEIKA; 1 of its 2 listed competitors has raised funding.
Company details
Develoepr of noninvasive neurostimulation treatments for mental health disorders. The company uses proprietary technology is Deep TMS, or Deep Transcranial Magnetic Stimulation, which launches a new era in brain disorder treatment. It is used to treat depressive episodes in patients suffering from Major Depressive Disorder.
- Headquarters Jerusalem, Israel
- Employees 120
- Stage Public
- SectorsHealthcare
- Website category Health · Mental Health
- Email••••••••
- Website brainsway.com
- Social LinkedIn X Facebook Instagram
- Legal Name Brainsway Ltd
- Annual Revenue$56.49 M (USD)18.64as on Dec 31, 2025
- Net Profit$8.19 M (USD)141.64as on Dec 31, 2025
- EBITDA$6.34 M (USD)72.72as on Dec 31, 2025
- Latest Funding Round$20M (USD), Post-IPO
Sep 2024
- InvestorsFnx
& 3 more
- Employee Count120
Products & Services of Brainsway
Brainsway offers a comprehensive portfolio of products and services, including Deep TMS Device, Deep TMS for MDD, and Deep TMS for OCD.
Noninvasive technology for treating mental health disorders
FDA-cleared therapy for major depressive disorder
Treatment for obsessive-compulsive disorder symptoms
Funding Insights of Brainsway
- Total Rounds 4
- Last Round Post-IPO — $20M
- First Round $11.8M
(Mar 2014)
- Investors Count 4
All 4 funding rounds of Brainsway with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2024 | $20M | Post-IPO | – | – | – |
| Dec 2017 | $8.5M | Post-IPO | – | – | |
| Jan 2016 | $163,712 | Grant | – | – | |
| Mar 2014 | $11.8M | Post-IPO | – | – | – |
4 investors in total: 4 institutional.
Investors in Brainsway
Brainsway has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include Fnx, IBI Investment House and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified insurance services are provided across various sectors by Fnx. | 1949 | fnx.co.il | - | |
Manages hedge funds focused on Israeli stocks, bonds, and distressed assets. | 2013 | noked-capital.com | Herzliya, Israel | |
Private fund focused on debt and equity investment in real estate and funds of funds focused on multiple sectors | 2013 | ibi.co.il | Tel Aviv, Israel | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Brainsway
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Brainsway
24 people are tracked at Brainsway (10 in leadership, 11 in board & advisors, 3 in team); the tracked headcount is 120.
| Name | Role | Group |
|---|---|---|
Moria Ben Soussan | VP, Research & Development | Leadership |
Hadar Levy | CEO | Leadership |
Yiftach Roth | Founder & CSO | Leadership |
Udi Ofek | Head Of Software Development | Leadership |
Michael Cohen | Vice President Of Sales | Leadership |
Yakir Yekutiely | Head Of International Business Intelligence & Digital Performance | Leadership |
Menachem C. Klein | VP, General Counsel & Corporate Secretary | Leadership |
Ido Marom | CFO | Leadership |
Ross Mitchell | Vice President Of Global Marketing | Leadership |
Joseph Levental | Director Of Global Sales | Leadership |
David Feifel | Advisor | Board & advisors |
Mark Hallett | Advisor | Board & advisors |
Mark S. George | Advisor | Board & advisors |
Avner Hagai | Director | Board & advisors |
Karen Sarid | Director | Board & advisors |
Yossi Ben Shalom | Director | Board & advisors |
David Zacut | Chairman, Board of Directors | Board & advisors |
Avner Lushi | Director | Board & advisors |
Markus Heilig | Scientific Advisor | Board & advisors |
Zafiris Daskalakis | Advisor | Board & advisors |
4 more people are available in the full profile.
Complete people profiles for Brainsway
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Brainsway
Brainsway is a publicly listed company on the TASE with ticker symbol BWAY in Israel, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Apr 2019
- Listed onNASDAQ: BWAY
- Listed entityBrainsway Ltd
- Exchange sectorHealth technology
- ISINIL0011007189
- Share price3,635.00 ILA (-2.52% on the day) · 2026-10-14
- Market capitalisation1,501,033,919.00 ILA
- Price to earnings48.8
- EPS (diluted, trailing year)0.74 ILA
- Volume (last session)19,182
Financials of Brainsway
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 180.1M ILS | 26.1M ILS | 20.2M ILS |
| 2024 | 151.8M ILS | 10.8M ILS | 11.7M ILS |
| 2023 | 117.2M ILS | -15.5M ILS | -13.2M ILS |
| 2022 | 91.3M ILS | -44.9M ILS | -34.7M ILS |
| 2021 | 95.8M ILS | -20.9M ILS | -6.2M ILS |
Detailed financial statements for Brainsway
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Brainsway
4 dated milestones of Brainsway across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Brainsway is founded.
- Funding First funding round of $11.8M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $20.0M.
Competitors of Brainsway
Brainsway has 2 listed competitors in our database, 1 of them funded. They include Magnus Medical and SYNEIKA, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| magnusmed.com | 2017 | Burlingame, United States | $88.99M | 38 | Non-invasive neuromodulation systems for depression treatment are provided. | |
| syneika.fr | 2009 | Rennes, France | – | – | Offers medical equipment for non-invasive brain stimulation therapies like TMS. |
Detailed competitors of Brainsway
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Brainsway
The website of Brainsway (brainsway.com) receives about 92.8K visits a month and ranks #579,331 among all websites worldwide, #907 in Mental Health.
- Monthly visits92.8K
▲ 42% vs previous month
- Unique visitors32.1K
per month
- Global rank#579,331
among all websites
- Category rank#907
Health · Mental Health
- Bounce rate51%
- Pages per visit1.6
- Average visit32 sec
- DevicesDesktop 29% · Mobile 71%
Websites whose visitors overlap most with Brainsway. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
peaceofmind.com | peaceofmind.com | 100% | – | #1,833,125 | – |
ocdtypes.com | ocdtypes.com | 94% | – | #1,209,043 | – |
mindcarecentres.com | mindcarecentres.com | 89% | – | – | – |
| calmsage.com | 85% | 54.6K | #696,557 | View details | |
harleytherapy.co.uk | harleytherapy.co.uk | 82% | – | #298,182 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 39 similar websites and full traffic analytics for Brainsway
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 39 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Neurology
10 companies that operate in the same segment as Brainsway (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | 541 | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Brainsway
Complete news archive for Brainsway
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Brainsway
Brainsway was founded in 2003 and raised its 1st funding round 11 years after it was founded.
Brainsway is headquartered in Jerusalem, Israel. It is registered at Jerusalem, Jerusalem District, Israel.
Brainsway has 120 employees.
Annual revenue of Brainsway is $56.49M as on Dec 31, 2025.
Develoepr of noninvasive neurostimulation treatments for mental health disorders. The company uses proprietary technology is Deep TMS, or Deep Transcranial Magnetic Stimulation, which launches a new era in brain disorder treatment. It is used to treat depressive episodes in patients suffering from Major Depressive Disorder.
Brainsway's top competitors include Magnus Medical and SYNEIKA.
Brainsway offers Deep TMS Device, Deep TMS for MDD, and Deep TMS for OCD.
Yes, Brainsway is publicly traded on TASE under the ticker symbol BWAY.
Brainsway has 4 investors. Key investors include Fnx, IBI Investment House, European Union, and Noked Capital.
Brainsway operates through Brainsway Ltd.